Literature DB >> 23410936

Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome.

Michael A Kiebish1, Kui Yang, Xinping Liu, David J Mancuso, Shaoping Guan, Zhongdan Zhao, Harold F Sims, Rebekah Cerqua, W Todd Cade, Xianlin Han, Richard W Gross.   

Abstract

Barth syndrome is a complex metabolic disorder caused by mutations in the mitochondrial transacylase tafazzin. Recently, an inducible tafazzin shRNA knockdown mouse model was generated to deconvolute the complex bioenergetic phenotype of this disease. To investigate the underlying cause of hemodynamic dysfunction in Barth syndrome, we interrogated the cardiac structural and signaling lipidome of this mouse model as well as its myocardial bioenergetic phenotype. A decrease in the distribution of cardiolipin molecular species and robust increases in monolysocardiolipin and dilysocardiolipin were demonstrated. Additionally, the contents of choline and ethanolamine glycerophospholipid molecular species containing precursors for lipid signaling at the sn-2 position were altered. Lipidomic analyses revealed specific dysregulation of HETEs and prostanoids, as well as oxidized linoleic and docosahexaenoic metabolites. Bioenergetic interrogation uncovered differential substrate utilization as well as decreases in Complex III and V activities. Transgenic expression of cardiolipin synthase or iPLA2γ ablation in tafazzin-deficient mice did not rescue the observed phenotype. These results underscore the complex nature of alterations in cardiolipin metabolism mediated by tafazzin loss of function. Collectively, we identified specific lipidomic, bioenergetic, and signaling alterations in a murine model that parallel those of Barth syndrome thereby providing novel insights into the pathophysiology of this debilitating disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410936      PMCID: PMC3622326          DOI: 10.1194/jlr.M034728

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  84 in total

1.  Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency.

Authors:  Meghan S Soustek; Darin J Falk; Cathryn S Mah; Matthew J Toth; Michael Schlame; Alfred S Lewin; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2011-05-19       Impact factor: 5.695

2.  The function of the adenine nucleotide translocator in the control of oxidative phosphorylation.

Authors:  R Bohnensack; F N Gellerich; L Schild; W Kunz
Journal:  Biochim Biophys Acta       Date:  1990-07-25

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 4.  Epoxyeicosatrienoic acid analogs and vascular function.

Authors:  V Sudhahar; S Shaw; J D Imig
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

5.  Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome.

Authors:  Riekelt H Houtkooper; Richard J Rodenburg; Charlotte Thiels; Henk van Lenthe; Femke Stet; Bwee Tien Poll-The; Janet E Stone; Colin G Steward; Ronald J Wanders; Jan Smeitink; Willem Kulik; Frédéric M Vaz
Journal:  Anal Biochem       Date:  2009-01-31       Impact factor: 3.365

6.  Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function.

Authors:  Dairong Wang; Vickas V Patel; Emanuela Ricciotti; Rong Zhou; Mark D Levin; Ehre Gao; Zhou Yu; Victor A Ferrari; Min Min Lu; Junwang Xu; Hualei Zhang; Yiqun Hui; Yan Cheng; Nataliya Petrenko; Ying Yu; Garret A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-17       Impact factor: 11.205

7.  Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome.

Authors:  Michael Schlame; Jeffrey A Towbin; Paul M Heerdt; Roswitha Jehle; Salvatore DiMauro; Thomas J J Blanck
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

Review 8.  The role of cardiolipin in the structural organization of mitochondrial membranes.

Authors:  Michael Schlame; Mindong Ren
Journal:  Biochim Biophys Acta       Date:  2009-05-04

9.  Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome.

Authors:  Ashim Malhotra; Irit Edelman-Novemsky; Yang Xu; Heide Plesken; Jinping Ma; Michael Schlame; Mindong Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

10.  Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction.

Authors:  Colin K L Phoon; Devrim Acehan; Michael Schlame; David L Stokes; Irit Edelman-Novemsky; Dawen Yu; Yang Xu; Nitya Viswanathan; Mindong Ren
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

View more
  62 in total

Review 1.  Mitochondrial dysfunctions in barth syndrome.

Authors:  Sagnika Ghosh; Donna M Iadarola; Writoban Basu Ball; Vishal M Gohil
Journal:  IUBMB Life       Date:  2019-02-11       Impact factor: 3.885

Review 2.  Cardiolipin signaling mechanisms: collapse of asymmetry and oxidation.

Authors:  Valerian E Kagan; Yulia Y Tyurina; Vladimir A Tyurin; Dariush Mohammadyani; Jose Pedro Friedmann Angeli; Sergei V Baranov; Judith Klein-Seetharaman; Robert M Friedlander; Rama K Mallampalli; Marcus Conrad; Hülya Bayir
Journal:  Antioxid Redox Signal       Date:  2015-03-31       Impact factor: 8.401

Review 3.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

4.  Overexpression of branched-chain amino acid aminotransferases rescues the growth defects of cells lacking the Barth syndrome-related gene TAZ1.

Authors:  Diana Antunes; Arpita Chowdhury; Abhishek Aich; Sreedivya Saladi; Nofar Harpaz; Mark Stahl; Maya Schuldiner; Johannes M Herrmann; Peter Rehling; Doron Rapaport
Journal:  J Mol Med (Berl)       Date:  2019-01-03       Impact factor: 4.599

5.  Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast.

Authors:  Matthew G Baile; Murugappan Sathappa; Ya-Wen Lu; Erin Pryce; Kevin Whited; J Michael McCaffery; Xianlin Han; Nathan N Alder; Steven M Claypool
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

6.  Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency.

Authors:  Tomohiro Kimura; Atsuko K Kimura; Mindong Ren; Bob Berno; Yang Xu; Michael Schlame; Richard M Epand
Journal:  Biochemistry       Date:  2018-03-30       Impact factor: 3.162

7.  Murine diet-induced obesity remodels cardiac and liver mitochondrial phospholipid acyl chains with differential effects on respiratory enzyme activity.

Authors:  E Madison Sullivan; Amy Fix; Miranda J Crouch; Genevieve C Sparagna; Tonya N Zeczycki; David A Brown; Saame Raza Shaikh
Journal:  J Nutr Biochem       Date:  2017-04-12       Impact factor: 6.048

8.  AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.

Authors:  Silveli Suzuki-Hatano; Madhurima Saha; Skylar A Rizzo; Rachael L Witko; Bennett J Gosiker; Manashwi Ramanathan; Meghan S Soustek; Michael D Jones; Peter B Kang; Barry J Byrne; W Todd Cade; Christina A Pacak
Journal:  Hum Gene Ther       Date:  2018-10-03       Impact factor: 5.695

9.  Dysregulation of cardiolipin biosynthesis in pediatric heart failure.

Authors:  Kathryn C Chatfield; Genevieve C Sparagna; Carmen C Sucharov; Shelley D Miyamoto; Jonathan E Grudis; Rebecca D Sobus; Jamie Hijmans; Brian L Stauffer
Journal:  J Mol Cell Cardiol       Date:  2014-06-14       Impact factor: 5.000

Review 10.  Lipidomics for studying metabolism.

Authors:  Xianlin Han
Journal:  Nat Rev Endocrinol       Date:  2016-07-29       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.